Accès gratuit
Numéro
Med Sci (Paris)
Volume 25, Numéro 12, Décembre 2009
Anticorps monoclonaux en thérapeutique
Page(s) 1070 - 1077
Section I - De la conception à la production
DOI https://doi.org/10.1051/medsci/200925121070
Publié en ligne 15 décembre 2009
  1. Van Walle I, Gansemans Y, Parren PW, et al. Immunogenicity screening in protein drug development. Expert Opin Biol Ther 2007; 7 : 405–18. [Google Scholar]
  2. Hwang W, Foote J. Immunogenicity of engineered antibodies. Methods 2005; 36 : 3–10. [Google Scholar]
  3. European agency for the evaluation of medicinal products (EMEA). Guideline on immunogenicity assessment of biotechnology-derived therapeutic proteins. EMEA/CHMP/BMWP/14327/2006, april 2008. [Google Scholar]
  4. Baert F, Noman M, Vermeire S, et al. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn’s disease. N Engl J Med 2003; 348 : 601–8. [Google Scholar]
  5. Goldstein G, Fuccello AJ, Norman DJ, et al. OKT3 monoclonal antibody plasma levels during therapy and the subsequent development of host antibodies to OKT3. Transplantation 1986; 42 : 507–11. [Google Scholar]
  6. Schroeder TJ, First MR, Hurtubise PE, et al. Immunologic monitoring with Orthoclone OKT3 therapy. J Heart Transplant 1989; 8 : 371–80. [Google Scholar]
  7. Bachmann MF, Rohrer UH, Kundig TM, et al. The influence of antigen organization on B cell responsiveness. Science 1993; 262 : 1448–51. [Google Scholar]
  8. Casadevall N, Nataf J, Viron B, et al. Pure red-cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin. N Engl J Med 2002; 346 : 469–75. [Google Scholar]
  9. Gupta S, Indelicato SR, Jethwa V, et al. Recommendations for the design, optimization, and qualification of cell-based assays used for the detection of neutralizing antibody responses elicited to biological therapeutics, J Immunol Methods 2007; 321 : 1–18. [Google Scholar]
  10. Koren E, Smith HW, Shores E, et al. Recommendations on risk-based strategies for detection and characterization of antibodies against biotechnology products. J Immunol Methods 2008; 333 : 1–9. [Google Scholar]
  11. Mire-Sluis AR, Barrett YC, Devanarayan V, et al. Recommendations for the design and optimization of immunoassays used in the detection of host antibodies against biotechnology products. J Immunol Methods 2004; 289 : 1–16. [Google Scholar]
  12. Shankar G, Devanarayan V, Amaravadi L, et al. Recommendations for the validation of immunoassays used for detection of host antibodies against biotechnology products. Biomed Anal 2008 online. [Google Scholar]
  13. Piro LD, White CA, Grillo-López AJ, et al. Extended Rituximab (anti-CD20 monoclonal antibody) therapy for relapsed or refractory low-grade or follicular non-Hodgkin’s lymphoma. Ann Oncol 1999; 10 : 655–61. [Google Scholar]
  14. Davis TA, Grillo-López AJ, White CA, et al. Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin’s lymphoma : safety and efficacy of re-treatment. J Clin Oncol 2000; 18 : 3135–43. [Google Scholar]
  15. Looney RJ, Anolik JH, Campbell D, et al. B cell depletion as a novel treatment for systemic lupus erythematosus : a phase I/II dose-escalation trial of rituximab. Arthritis Rheum 2004; 50 : 2580–9. [Google Scholar]
  16. Pijpe J, van Imhoff GW, Spijkervet FK, et al. Rituximab treatment in patients with primary Sjögren’s syndrome : an open-label phase II study. Arthritis Rheum 2005; 52 : 2740–50. [Google Scholar]
  17. van de Putte LB, Atkins C, Malaise M, et al. Efficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failed. Ann Rheum Dis 2004; 63 : 508–16. [Google Scholar]
  18. Keystone EC, Kavanaugh AF, Sharp JT, et al. Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy : a randomized, placebo-controlled, 52-week trial. Arthritis Rheum 2004; 50 : 1400–11. [Google Scholar]
  19. Bender NK, Heilig CE, Droll B, et al. Immunogenicity, efficacy and adverse events of adalimumab in RA patients. Rheumatol Int 2007; 27 : 269–74. [Google Scholar]
  20. Rammensee H, Bachmann J, Emmerich NP, et al. SYFPEITHI : database for MHC ligands and peptide motifs. Immunogenetics 1999; 50 : 213–9. [Google Scholar]
  21. Sturniolo T, Bono E, Ding J, et al. Generation of tissue-specific and promiscuous HLA ligand databases using DNA microarrays and virtual HLA class II matrices. Nat Biotechnol 1999; 17 : 555–61. [Google Scholar]
  22. Desmet J, Meersseman G, Boutonnet N, et al. Anchor profiles of HLA-specific peptides : analysis by a novel affinity scoring method and experimental validation. Proteins 2005; 58 : 53–69. [Google Scholar]
  23. Falk K, Roetzschke O, Stefanovic S, et al. Allele-specific motifs revealed by sequencing of self-peptides eluted from MHC molecules. Nature 1991; 351 : 290–6. [Google Scholar]
  24. Davenport MP, Smith KJ, Barouch D, et al. HLA Class I binding motifs derived from random peptide libraries differ at the COOH terminus from those of eluted peptides. J Exp Med 1997; 185 : 367–71. [Google Scholar]

Les statistiques affichées correspondent au cumul d'une part des vues des résumés de l'article et d'autre part des vues et téléchargements de l'article plein-texte (PDF, Full-HTML, ePub... selon les formats disponibles) sur la platefome Vision4Press.

Les statistiques sont disponibles avec un délai de 48 à 96 heures et sont mises à jour quotidiennement en semaine.

Le chargement des statistiques peut être long.